Products Under Development

as of May 10, 2024

We will taken on the challenge of “drug discovery innovation” to create new value by combining drug discovery technologies and disease research.

And also, we will expand target modalities and disease fields and pursue in-licensing initiatives in a wide range of areas to broaden our development pipeline, and proactive partnering activities.

Ph3 ~ Application submitted

Stage Compound / Code Origin Features
PhⅢ(Sep 2022) KRP-R120
/ Interstitial lung disease: ILD (pulmonary sarcoidosis)
aTyr pharma It is a fusion protein drug having the action to suppress, by binding to neuropilin-2 (NRP2) receptor, the excessive activation of immune cells, and is a potential first-in-class therapy to treat inflammatory diseases such as pulmonary sarcoidosis.

POC Project (Ph1 ~ Ph2)

Stage Compound / Code Origin Features
PhⅠ(Aug 2022) KRP-114VP / Overactive bladder Merck Additional Indication for Beova in pediatric patients.
PhⅠ(Apr 2021) KRP-A218 In-house It is antiviral drug that suppresses viral growth by targeting host molecules.

Licensing development (License-in)

Stage Compound / Code Origin Features
PhⅡ(Dec 2019)
ASKA Pharmaceutical
AKP-009 / Benign Prostatic Hyperplasia ASKA Pharmaceutical Novel androgen receptor modulator mode of action with the potential to exhibit prostatic shrinkage and to improve urinary function as a novel therapeutic agent for Benign Prostatic Hyperplasia.

* Additional Ph1 study at a higher dose has been completed (ASKA)

Licensing development (License-out)

Stage/Overseas Compound / Code Licensee Origin Features
PhⅢ KRP-203 Priothera In-house Sphingosine-1-Phosphate Receptor Agonist.


Origin Code Proposed Indication Note
SUSMED KRP-DT123 Tinnitus Collaboration research and sales agreement for development of Digital Therapeutics (DTx) in otolaryngology Field (Nov 2022)
Specified clinical trial is in progress.